Corporate Profile
HCW Biologics is a clinical-stage company advancing the development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.
HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.
HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index
Data Provided by Refinitiv. Minimum 15 minutes delayed.
| Filing date | Description | Form |
|---|---|---|
UPLOAD |
UPLOAD | |
UPLOAD |
UPLOAD | |
UPLOAD |
UPLOAD | |
Filing by person(s) reporting owned shares of common stock in a public company >5% |
SC 13D | |
Securities offered to employees pursuant to employee benefit plans |
S-8 | |
Simplified registration form |
S-3 | |
Registration of up to an additional 20% of securities for any offering registered on an S-1 |
S-1MEF |